Metagenomi Therapeutics (MGX) Asset Writedowns and Impairment (2023 - 2025)
Metagenomi Therapeutics (MGX) reported Asset Writedowns and Impairment of $181000.0 for Q2 2025, down 34.18% year-over-year from $275000.0 in Q2 2024, and down 75.93% quarter-over-quarter from $752000.0 in Q4 2024.
Metagenomi Therapeutics (MGX) Asset Writedowns and Impairment (2023 - 2025) Analysis & Trends
Metagenomi Therapeutics (MGX) has 3 years of Asset Writedowns and Impairment data on file, last reported at $181000.0 in Q2 2025.
- Asset Writedowns and Impairment for Q2 2025 came in at $181000.0, down 34.18% year-over-year; the trailing twelve-month figure through Sep 2025 was $933000.0 (up 206.91% YoY), and the FY2024 annual result was $1.0 million, up 4430.43% from the prior year.
- Asset Writedowns and Impairment fell to $181000.0 in Q2 2025 per MGX's latest filing, from $752000.0 in the prior quarter.
- Over five years, Asset Writedowns and Impairment peaked at $752000.0 in Q4 2024 and troughed at $4000.0 in Q1 2024.
- A 3-year average of $206166.7 and a median of $97500.0 in 2023 frame the typical range for Asset Writedowns and Impairment.
- The sharpest annual moves came in 2024 and 2025: Asset Writedowns and Impairment surged 5271.43% in 2024, then slumped 34.18% in 2025.
- A 3-year view of Asset Writedowns and Impairment shows it stood at $14000.0 in 2023, then surged by 5271.43% to $752000.0 in 2024, then slumped by 75.93% to $181000.0 in 2025.
- Business Quant data shows MGX's Asset Writedowns and Impairment at $181000.0 in Q2 2025, $752000.0 in Q4 2024, and $11000.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 821,726.73 Bn | 821,726.69 Bn | - |
| 2 | Belite Bio | 57,768.00 Bn | 57,768.00 Bn | - |
| 3 | Quantum Biopharma | 16,655.88 Bn | 16,655.88 Bn | - |
| 4 | Legend Biotech | 3,540.00 Bn | 3,539.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,526.26 Bn | 1,526.24 Bn | - |
| 6 | Akari Therapeutics | 1,520.09 Bn | 1,520.09 Bn | - |
| 7 | Psyence Biomedical | 223.87 Bn | 223.87 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.47 Bn | 107.23 Bn | 2.59 Bn |
| 9 | Abivax | 91.22 Bn | 91.22 Bn | - |
| 10 | Metagenomi Therapeutics | 42.84 Mn | 42.84 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 181,000.00 |
| Jun 30, 2025 | 181,000.00 |
| Dec 31, 2024 | 752,000.00 |
| Dec 31, 2024 | 752,000.00 |
| Sep 30, 2024 | 11,000.00 |
| Sep 30, 2024 | 11,000.00 |
| Jun 30, 2024 | 275,000.00 |
| Jun 30, 2024 | 275,000.00 |
| Mar 31, 2024 | 4,000.00 |
| Mar 31, 2024 | 4,000.00 |
| Dec 31, 2023 | 14,000.00 |
| Dec 31, 2023 | 14,000.00 |